索拉菲尼的疗效如何?

lantian

家人吃易和化疗无效, 医生说再治疗就是吃特罗凯或索拉菲尼了，请问有用过索拉菲尼的么，疗效如何?

努力的小白

索拉菲尼一个疗程5万，4个疗程20万以后公司全包。但是，家里有钱吗？而且，索拉菲尼的有效率很低，大概在10%上下，还包括了吃易瑞沙和特罗凯耐药后的人群，且针对肾和肝，肺部在临床中。

棕若有情天

厄，那不等于易要素无效，特在不行，就没办法了

lantian

QUOTE:

以下是引用努力的小白在2008-2-20 10:54:46的发言：
索拉菲尼一个疗程5万，4个疗程20万以后公司全包。但是，家里有钱吗？而且，索拉菲尼的有效率很低，大概在10%上下，还包括了吃易瑞沙和特罗凯耐药后的人群，且针对肾和肝，肺部在临床中。

目前我们的选择不多了, 只能尽量试试了. 医生说索拉菲尼和特罗凯这两种药,让我们选其中一种.

索拉菲尼的有效率很低么? 能不能详细说说?

以马内利

lantian，索拉非尼对非小细胞肺癌的有效率是比较低的，索拉非尼主要是治疗晚期肾癌的，对非小细胞肺癌的治疗作用还处于临床试验阶段，目前我们奇迹网的病友里使用过索拉非尼的病友很少，我知道的不超过5例，效果大都不明显或者是不好判断，之所以这么关注索拉非尼也就是因为它是多靶点的，是出于对靶向药物的信心，尤其是单靶点药物易瑞沙良好的临床效果。我也是觉得主要取决于经济因素，如果经济上能够承受，个人认为索拉非尼这个方案优于特罗凯。

lantian

谢谢以马。

我们的医生也说他们的病例数不多,他手头有一个病人,吃易瑞莎2个月耐药,再吃特罗凯3个月耐药,现在吃索拉非尼,5个月了,还有效.但他说因病例数少，没有统计学意义，就象吃中药，有效无效，事先谁也不知道。

以马内利

不客气的lantian，能够帮得上的也很有限，对于索拉非尼就是临床反馈太少了，我记得去年小路服用索拉非尼的时候咨询销售人员说整个上海地区用索拉非尼治疗肺癌的屈指可数。

jimmy112199

有效率60%，见所附2期试药结果

Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma.

Sub-category: Non-Small Cell Lung Cancer Category: Lung Cancer Meeting: 2006 ASCO Annual Meeting

Printer Friendly E-Mail Article

Abstract No:	7002
Citation:	Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 7002
Author(s):	U. Gatzemeier, G. Blumenschein, F. Fosella, R. Simantov, J. Elting, D. Bigwood, F. Cihon, M. Reck
Abstract:	Background: Sorafenib, an oral multi-kinase inhibitor, targets the Raf/MEK/ERK pathway at the level of Raf kinase and receptor tyrosine kinases, and has shown efficacy against several tumor types in phase I/II trials. Non-small-cell lung cancer (NSCLC) is associated with mutations in k-ras, upstream of Raf/MEK/ERK. Methods: This multi-center, uncontrolled, phase II trial evaluated efficacy (every 8 weeks using RECIST) and safety of sorafenib (400 mg bid, continuous) in patients with relapsed or refractory advanced NSCLC. Plasma for proteomic biomarker analysis (ELISA [n=44]; mass-spectrometry [n=43]) was taken at screening, Day 21 of Cycle 1, and Day 1 of Cycle 3. Results: Fifty-two of 54 patients enrolled received sorafenib. Most (49/52) patients who received sorafenib had stage IV NSCLC. Thirty patients (59%) out of 51 evaluable for efficacy had SD. Although there were no confirmed PRs, tumor shrinkage was observed in 15 (29%) patients (four had >30% shrinkage). Patients with SD had a median progression-free survival (PFS) of 23.7 weeks, while all evaluable patients (n=51) had a median PFS of 11.9 weeks and median overall survival of 29.3 weeks. The most frequent drug-related adverse events observed in 52 patients were diarrhea (21 [40%] patients), hand-foot skin reaction (HFS; 19 [37%]), fatigue (14 [27%]), and nausea (13 [25%]). Frequent drug-related adverse events > grade 3 included HFS (n=5 [10%]) and hypertension (n=2 [4%]). Three patients discontinued due to adverse events (HFS, elevated lipase, and myocardial infarction). There were nine deaths within 30 days of discontinuation of sorafenib (n=5 PD; n=2 cardiopulmonary arrest; n=1 hemoptysis; and n=1 unknown cause). The levels of five proteins measured by ELISA, either at screening or change over treatment duration, correlated significantly with time to progression (TTP) or maximum tumor shrinkage. Levels of five additional proteins, identified by mass-spectrometry, also correlated with TTP. Conclusions: Identified biomarkers may help assess efficacy of sorafenib in NSCLC patients. Sorafenib 400 mg bid is generally well tolerated and shows promising efficacy in patients with advanced, progressive NSCLC, with approximately 60% of pts achieving disease stabilization.